22:12:20 EDT Tue 26 May 2020
Enter Symbol
or Name

Login ID:

Q:CYDY - CYTODYN INC - Website unknown - click to update22:12:20 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYDY - Qnot subscribed3.14+0.041.35,921.618,6394,3253.15  3.24  3.083.84  0.26116:08:26May 2215 min RT 2¢

Recent Trades - Last 10 of 4325
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2020-05-22 20:49U:CYDYNews ReleaseCytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS
2020-05-19 06:00U:CYDYNews ReleaseCytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population
2020-05-18 06:00U:CYDYNews ReleaseCytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir
2020-05-15 06:00U:CYDYNews ReleaseCytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19
2020-05-13 06:00U:CYDYNews ReleaseCytoDyn Completed Submission of All Remaining Parts of Biologics License Application ( “BLA ”) on May 11, 2020
2020-05-11 06:00U:CYDYNews ReleaseCytoDyn to Present at Wall Street Reporter ’s NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PT
2020-05-08 19:59U:CYDYNews ReleaseCytoDyn Clarifies Status of Biologics License Application
2020-05-08 17:00U:CYDYNews ReleaseGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors
2020-05-08 11:33U:CYDYNews ReleaseFederman & Sherwood Investigates CytoDyn Inc. for Possible Violations of Federal Securities Laws
2020-05-08 07:30U:CYDYNews ReleaseSHAREHOLDER ALERT: Investigation of CytoDyn Announced by Holzer & Holzer, LLC
2020-05-07 18:19U:CYDYNews ReleaseNovant Health Initiates Phase 2b/3 Trial with CytoDyn ’s Leronlimab for Severely and Critically Ill COVID-19 Patients
2020-05-06 01:24U:CYDYNews ReleaseManuscript Describes How CytoDyn ’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients
2020-05-04 12:57U:CYDYNews Release “Next Super Stocks ” in News: fuboTV (OTC: FUBO) Edgar Bronfman, Jr. Appointed Executive Chairman -   CytoDyn (OTC: CYDY) Reports Strong Results From COVID-19 Coronavirus Patients Treated with Leronlimab - NexTech AR Solutions (OTC: NEXCF) Acquires   Rem
2020-05-04 06:00U:CYDYNews ReleaseFDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for
2020-04-30 06:00U:CYDYNews ReleaseCytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries